Why Regeneron win is worse for Amgen than you think?

Amgen patent covering LDL cholestrol lowering drug Reapatha are likely to be invalidated in the wake of a courtbattle with Regeneron Pharmaceutical and Sanofi. Recently, a federal judge tossed an injunction on sales of Praluent, Regenron and Sanofi will argue that Amgen's patent are too broad. The judge's decision on Thursday effectively ended [...]

By |2017-10-07T15:09:31+05:30October 7th, 2017|Patent|0 Comments

Regeneron, Sanofi-Aventis sue for declaration that dermatitis treatment Dupixent doesn’t infringe Amgen patent

On Monday, March 20th, American pharmaceutical companies Sanofi-Aventis US, a subsidiary of France-based Sanofi S.A. (NYSE:SNY), and Regeneron (NASDAQ:REGN) were listed as plaintiffs in a suit filed to seek declaratory judgment of non-infringement of a patent held by American biopharma firm Amgen (NASDAQ:AMGN). Sanofi-Aventis and Regeneron are hoping to protect their market interest in a treatment developed to help patients [...]

By |2017-09-08T10:41:28+05:30March 30th, 2017|International, Patent|0 Comments

Sanofi, Regeneron lose bid to overturn Amgen

Sanofi (NYSE:SNY) and Regeneron Pharmaceuticals (NASDAQ:REGN) lose their bid to overturn a court verdict upholding two Amgen (NASDAQ:AMGN) patents covering cholesterol drug Repatha (evolocumab). Amgen sued the companies in August 2014 in an attempt to prevent them from selling rival drug Praluent (alirocumab). Both of them lower cholesterol by blocking a protein called PCSK9. [...]

By |2017-09-08T12:56:35+05:30January 5th, 2017|International, Patent|0 Comments
Go to Top